Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 104

1.

Concomitance of cardiovascular and pulmonary disorders: mutual bystanders or causal interactions?

Alter P, Jörres RA.

Kardiol Pol. 2018;76(7):1027-1028. doi: 10.5603/KP.2018.0132. No abstract available.

2.

Treatment options in myocarditis and inflammatory cardiomyopathy : Focus on i. v. immunoglobulins.

Maisch B, Alter P.

Herz. 2018 Jun 15. doi: 10.1007/s00059-018-4719-x. [Epub ahead of print]

PMID:
29947834
3.

Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach.

Kahnert K, Alter P, Welte T, Huber RM, Behr J, Biertz F, Watz H, Bals R, Vogelmeier CF, Jörres RA.

Respir Res. 2018 Jun 4;19(1):110. doi: 10.1186/s12931-018-0815-y.

4.

Left ventricular volume and wall stress are linked to lung function impairment in COPD.

Alter P, Jörres RA, Watz H, Welte T, Gläser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF.

Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.

PMID:
29657040
5.

The revised GOLD 2017 COPD categorization in relation to comorbidities.

Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Jan;134:79-85. doi: 10.1016/j.rmed.2017.12.003. Epub 2017 Dec 5.

6.

Prevalence of comorbidities in COPD patients by disease severity in a German population.

Greulich T, Weist BJD, Koczulla AR, Janciauskiene S, Klemmer A, Lux W, Alter P, Vogelmeier CF.

Respir Med. 2017 Nov;132:132-138. doi: 10.1016/j.rmed.2017.10.007. Epub 2017 Oct 12.

PMID:
29229085
7.

Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort.

Kahnert K, Lucke T, Huber RM, Behr J, Biertz F, Vogt A, Watz H, Alter P, Fähndrich S, Bals R, Holle R, Karrasch S, Söhler S, Wacker M, Ficker JH, Parhofer KG, Vogelmeier C, Jörres RA; COSYCONET consortium.

PLoS One. 2017 May 15;12(5):e0177501. doi: 10.1371/journal.pone.0177501. eCollection 2017.

8.

Feasibility and safety of whole-body vibration therapy in intensive care patients.

Alter P, Boeselt T, Nell C, Spielmanns M, Kenn K, Koczulla AR.

Crit Care. 2017 Apr 13;21(1):91. doi: 10.1186/s13054-017-1669-2. No abstract available.

9.

Benefits of High-Intensity Exercise Training to Patients with Chronic Obstructive Pulmonary Disease: A Controlled Study.

Boeselt T, Nell C, Lütteken L, Kehr K, Koepke J, Apelt S, Veith M, Beutel B, Spielmanns M, Greulich T, Vogelmeier CF, Kenn K, Janciauskiene S, Alter P, Koczulla AR.

Respiration. 2017;93(5):301-310. doi: 10.1159/000464139. Epub 2017 Mar 23.

10.

Myocardial homing of mesenchymal stem cells following intrapericardial application and amplification by inflammation - an experimental pilot study.

Jung N, Rupp H, Koczulla AR, Vogelmeier CF, Alter P.

Can J Physiol Pharmacol. 2017 Sep;95(9):1064-1066. doi: 10.1139/cjpp-2016-0373. Epub 2017 Feb 23.

11.

[Pulmonary Rehabilitation after Acute Exacerbation of COPD Reduces the Rate of Reexacerbations].

Spielmanns M, Meier A, Winkler A, Glöckl R, Nell C, Koczulla AR, Boeselt T, Alter P, Magnet F, Storre JH, Windisch W.

Dtsch Med Wochenschr. 2017 Jan;142(2):e10-e19. doi: 10.1055/s-0042-121346. Epub 2017 Jan 23. German.

PMID:
28114711
12.

Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort.

Kahnert K, Lucke T, Biertz F, Lechner A, Watz H, Alter P, Bals R, Behr J, Holle R, Huber RM, Karrasch S, Stubbe B, Wacker M, Söhler S, Wouters EF, Vogelmeier C, Jörres RA; COSYCONET study group.

Respir Res. 2017 Jan 13;18(1):14. doi: 10.1186/s12931-016-0499-0.

13.

Validity and Usability of Physical Activity Monitoring in Patients with Chronic Obstructive Pulmonary Disease (COPD).

Boeselt T, Spielmanns M, Nell C, Storre JH, Windisch W, Magerhans L, Beutel B, Kenn K, Greulich T, Alter P, Vogelmeier C, Koczulla AR.

PLoS One. 2016 Jun 15;11(6):e0157229. doi: 10.1371/journal.pone.0157229. eCollection 2016.

14.

Marine omega-3 highly unsaturated fatty acids: From mechanisms to clinical implications in heart failure and arrhythmias.

Glück T, Alter P.

Vascul Pharmacol. 2016 Jul;82:11-9. doi: 10.1016/j.vph.2016.03.007. Epub 2016 Apr 11. Review.

PMID:
27080538
15.

Whole-body vibration therapy in intensive care patients: A feasibility and safety study.

Boeselt T, Nell C, Kehr K, Holland A, Dresel M, Greulich T, Tackenberg B, Kenn K, Boeder J, Klapdor B, Kirschbaum A, Vogelmeier C, Alter P, Koczulla AR.

J Rehabil Med. 2016 Mar;48(3):316-21. doi: 10.2340/16501977-2052.

16.

RE: Relation of Late Gadolinium Enhancement to Increased Ventricular Wall Stress in Dilated Cardiomyopathy.

Alter P.

Korean J Radiol. 2016 Jan-Feb;17(1):171-2. doi: 10.3348/kjr.2016.17.1.171. Epub 2016 Jan 6. No abstract available.

17.

Mechanisms increasing n-3 highly unsaturated fatty acids in the heart.

Glück T, Rupp H, Alter P.

Can J Physiol Pharmacol. 2016 Mar;94(3):309-23. doi: 10.1139/cjpp-2015-0300. Epub 2015 Sep 17.

18.

Wall stress determines systolic and diastolic function--Characteristics of heart failure.

Alter P, Koczulla AR, Nell C, Figiel JH, Vogelmeier CF, Rominger MB.

Int J Cardiol. 2016 Jan 1;202:685-93. doi: 10.1016/j.ijcard.2015.09.032. Epub 2015 Sep 25.

PMID:
26454537
19.

From Heart Failure to Highly Unsaturated Fatty Acid Deficiency and Vice Versa: Bidirectional Heart and Liver Interactions.

Alter P, Glück T, Figiel JH, Koczulla AR, Vogelmeier CF, Rupp H.

Can J Cardiol. 2016 Feb;32(2):217-25. doi: 10.1016/j.cjca.2015.05.019. Epub 2015 May 30.

PMID:
26277086
20.

Airflow limitation in COPD is associated with increased left ventricular wall stress in coincident heart failure.

Alter P, van de Sand K, Nell C, Figiel JH, Greulich T, Vogelmeier CF, Koczulla AR.

Respir Med. 2015 Sep;109(9):1131-7. doi: 10.1016/j.rmed.2015.07.012. Epub 2015 Jul 17.

Supplemental Content

Loading ...
Support Center